LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.
Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings.
Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators.
In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome).
Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation.
What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.
As Sr. Manager, Supply Chain Planning, you will be responsible for developing end to end supply plans to ensure continuous drug supply for Corcept’s global clinical trials. This position will report to the Sr. Director, Supply Chain.
Responsibilities:
Develop supply plans for all Corcept clinical studies
Perform scenario planning to support decision-making
Provide clinical supply and risk mitigation recommendations
Oversee inventory management of study drug and comparators at depots
Maintain supply dashboards (eg. month-on-hand) and KPI’s
Work cross-functionally to ensure supply plans are feasible
Provide product costs to support international shipments
Develop and implement appropriate Supply Chain SOPs.
Preferred Skills, Qualifications and Technical Proficiencies:
Working experience with global clinical trials and IRT systems is a must
Working knowledge of cGMPs and familiarity with US and EU regulations
Working knowledge of drug development process (Phase I-IV)
Excellent interpersonal, verbal, and written communication skills are essential in this collaborative, fast-paced, dynamic environment
Excellent organizational skills and an ability to prioritize effectively to deliver results within established timelines
Strong attention to detail with excellent follow-up
Proficient in Microsoft Outlook, Word, Excel, PowerPoint
Preferred Education and Experience:
BS/BA degree in Life Science or a closely related field.
6-8 years of experience in a pharmaceutical or biotechnology company
ASCM CPIM/CSCP certifications preferred
The pay range that the Company reasonably expects to pay for this headquarters-based position is $165,000 - $185,000; the pay ultimately offered may vary based on legitimate considerations, including geographic location, job-related knowledge, skills, experience, and education.
Applicants must be currently authorized to work in the United States on a full-time basis.
For information on how Corcept collects, uses, discloses, protects, and otherwise processes personal information and an explanation of the rights and choices available to you with respect to your personal information, please refer to our Privacy Notice link.
Corcept appreciates the commitment and hard work of all our team members as we strive to discover and develop novel treatments for patients with serious unmet medical needs.
Corcept will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview. Though we use third-party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Corcept.
Seniority level
Mid-Senior level
Employment type
Full-time
Job function
Management and Manufacturing
Industries
Biotechnology Research
Referrals increase your chances of interviewing at Corcept Therapeutics by 2x